Disclosed is a use of from about 10 to about 500 tumour-antigen/MHC/co-stimulatory molecule complexes operatively coupled to a nanoparticle having a diameter of about 1 to about 100 nm in an amount sufficient to expand a population of antigen-specific T cells in the manufacture of a medicament for the treatment of a tumour or cancer wherein the nanoparticle comprises a metal or metal oxide core.
